Aug. 20, 2018 – The FDA continues to consider whether the amount and location of risk disclosure information currently appearing in direct-to-consumer (DTC) print ads – both in the brief summary and the “important safety information” (ISI) section – has the potential to “overwarn” consumers. In an FDA notice in the Federal Register last week, […]
Read more
Aug. 13, 2018 – The FDA released final details about the study it plans to conduct on the effectiveness of drug company disclosures in professional and consumer prescription drug promotion in an Aug. 9 Federal Register notice. Specifically, the aim of the research is to “examine the effectiveness of clear and conspicuous disclosures in prescription […]
Read more
Aug. 11, 2017 – The results of a recent study conducted by the FDA and RTI International has concluded that a revised, briefer risk statement in broadcast direct-to-consumer (DTC) ads improves risk and benefit recognition and risk recall. As such, a move toward communicating a limited number of risks and including a disclosure alerting consumers […]
Read more
Jan. 4, 2017 – The FDA will examine whether consumers and health care professionals (HCPs) can identify deceptive claims in prescription drug promotion, according to a notice published in today’s Federal Register. Results of the study could lead to an expansion of the FDA’s Bad Ad program to include consumer reporters. Although empirical research has […]
Read moreJuly 24, 2014 – A better understanding of how adolescents weigh risks and benefits in direct-to-consumer (DTC) ads is needed to address concerns the FDA has about this vulnerable population, the agency stated in a notice published July 21 in the Federal Register (2014-16998). “Adolescents are a unique audience for DTC drug marketing because their […]
Read more